VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | Understanding disease biology of AML to develop targeted therapies

VJHemOnc is committed to improving our service to you

Arnon Nagler

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses how understanding disease biology is crucial for the development of new targeted therapies. Prof. Nagler outlines that specific mutations were discovered in acute myeloid leukemia (AML); these were P53 and MP1. Additionally, other aspects of biology are important for drug development as well, such as the role of the microenvironment. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter